title: Effects of interferon-beta 1a on the hypothalamic-pituitary-adrenal axis, leukocyte distribution and mood states in multiple sclerosis patients: results of a 1-year follow-up study.
abstract: Acute interferon-beta (IFN-beta) administration transiently activates the hypothalamic-pituitary-adrenal (HPA) axis, increases granulocytes, and reduces lymphocytes in peripheral blood. To test whether these effects are still present after long-term treatment, 13 patients with relapsing-remitting multiple sclerosis were analyzed at baseline, and 1, 2, 4, and 8 h after IFN-beta 1a injection at two occasions: at the initial administration and after 1 year of continuous treatment. Long-term treatment reduced the responsiveness of the HPA axis to the injection, and abolished the distributional changes in leukocyte numbers. One-year treatment with IFN-beta 1a did not induce mood alterations as assessed by the Profile of Mood States. These results suggest that long-term IFN-beta therapy has a profound impact on leukocyte distribution and the neuroendocrine response to the drug.
authors.affiliation: Department of Medical Psychology, Medical Faculty, Division of Endocrinology, University of Duisburg-Essen, Duisburg-Essen, Germany.
authors.forename: Marion U
authors.initials: MU
authors.lastname: Goebel
authors.forename: Frank
authors.initials: F
authors.lastname: Czolbe
authors.forename: Holger
authors.initials: H
authors.lastname: Becker
authors.forename: Onno E
authors.initials: OE
authors.lastname: Janssen
authors.forename: Manfred
authors.initials: M
authors.lastname: Schedlowski
authors.forename: Volker
authors.initials: V
authors.lastname: Limmroth
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000339:Affect / Q000187:drug effects* / Q000502:physiology; D001831:Body Temperature / Q000187:drug effects; D002452:Cell Count / Q000379:methods; D004185:Disability Evaluation; D005221:Fatigue / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000494:pharmacology* / Q000627:therapeutic use; D007962:Leukocytes / Q000145:classification / Q000187:drug effects; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone; D000068556:Interferon beta-1a